{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:11:52Z","timestamp":1787965912212,"version":"build-2784847793"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,1,15]]},"DOI":"10.2169\/internalmedicine.2743-23","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:14:20Z","timestamp":1715811260000},"page":"251-259","source":"Crossref","is-referenced-by-count":2,"title":["A Male Japanese Patient with Temple Syndrome Complicated by Type 2 Diabetes Mellitus"],"prefix":"10.2169","volume":"64","author":[{"given":"Masanori","family":"Iwanishi","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Omi Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Yorifuji","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Date Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Omi Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ito-Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Omi Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Omi Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kikugawa","sequence":"additional","affiliation":[{"name":"DNA Chip Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Temple IK, Cockwell K, Hassold T, Pettay D, Jacobs P. Maternal uniparental disomy for chromosome 14. J Med Genet 28: 511-514, 1991.","DOI":"10.1136\/jmg.28.8.511"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ioannides Y, Lokulo-Sodipe K, Mackay DJG, Davis JH, Temple IK. Temple syndrome: improving the recognition of an underdiagnosed chromosome 14 imprinting disorder: an analysis of 51 published cases. J Med Genet 51: 495-501, 2014.","DOI":"10.1136\/jmedgenet-2014-102396"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. da Silva C, Durandt C, Kallmeyer K, Ambele MA, Pepper MS. The role of Pref-1 during adipogenic differentiation: an overview of suggested mechanisms. Int J Mol Sci 21: 4104, 2020.","DOI":"10.3390\/ijms21114104"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Moon YS, Smas CM, Lee K, et al. Mice lacking paternally expressed Pref-1\/Dlk 1 display growth retardation and accelerated adiposity. Mol Cell Biol 22: 5585-5592, 2002.","DOI":"10.1128\/MCB.22.15.5585-5592.2002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitazawa M, Hayashi S, Imamura M, et al. Deficiency and overexpression of <i>Rtl1<\/i> in the mouse cause distinct muscle abnormalities related to Temple and Kagami-Ogata syndromes. Development 147: dev185918, 2020.","DOI":"10.1242\/dev.185918"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kagami M, Nagasaki K, Kosaki R, et al. Temple syndrome: comprehensive molecular and clinical findings in 32 Japanese patients. Genet Med 19: 1356-1366, 2017.","DOI":"10.1038\/gim.2017.53"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kagami M, Yanagisawa A, Ota M, et al. Temple syndrome in a patient with variability methylated CpGs at the primary <i>MEG3\/DLK1<\/i>:IG-DMR and severely hypomethylated CpGs at the secondary <i>MEG3<\/i>:TSS-DMR. Clin Epigenet 11: 42, 2019.","DOI":"10.1186\/s13148-019-0640-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kagami M, Kato F, Matsubara K, Sato T, Nishimura G, Ogata T. Relative frequency of underlying genetic causes for the development of UPD(14)pat-like phenotype. Eur J Hum Genet 20: 928-932, 2012.","DOI":"10.1038\/ejhg.2012.26"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hosoe J, Miya F, Kadowaki H, et al. Clinical usefulness of multigene screening with phenotype-driven bioinformatics analysis for the diagnosis of patients with monogenic diabetes or severe insulin resistance. Diabetes Res Clin Pract 169: 108461, 2020.","DOI":"10.1016\/j.diabres.2020.108461"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yamada C, Mitsuhashi T, Hiratsuka N, Inabe F, Araida N, Takahashi E. Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population. J Diabetes Invest 2: 373-376, 2011.","DOI":"10.1111\/j.2040-1124.2011.00113.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takahara M, Katakami N, Kaneto H, Noguchi M, Shimomura I. Distribution of the Matsuda Index in Japanese healthy subjects. J Diabetes Invest 4: 369-371, 2013.","DOI":"10.1111\/jdi.12056"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Komada H, Sakaguchi K, Takeda K, et al. Age-dependent decline in \u03b2-cell function assessed by an oral glucose tolerance test-based disposition index. J Diabetes Invest 2: 293-296, 2011.","DOI":"10.1111\/j.2040-1124.2010.00099.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Horie I, Abiru N, Eto M, et al. Sex differences in insulin and glucagon responses for glucose homeostasis in young healthy Japanese adults. J Diabetes Invest 9: 1283-1287, 2018.","DOI":"10.1111\/jdi.12829"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Meral R, Ryan BJ, Malandrino N, et al. Fat shadows from DEXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers. Diabetes Care 41: 2255-2258, 2018.","DOI":"10.2337\/dc18-0978"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen LK, Woo J, Assantachal P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21: 300-307, 2020.","DOI":"10.1016\/j.jamda.2019.12.012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hamaguchi T, Hirota Y, Takeuchi T, et al. Treatment of a case of severe insulin resistance as a result of a <i>PIK3R1<\/i> mutation with a sodium-glucose cotransporter 2 inhibitor. J Diabetes Investig 9: 1224-1277, 2018.","DOI":"10.1111\/jdi.12825"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bansal R, Cochran E, Startzell M, Brown RJ. Clinical effects of sodium-glucose transporter type 2 inhibitors in patients with partial lipodystrophy. Endocr Pract 28: 610-614, 2022.","DOI":"10.1016\/j.eprac.2022.03.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Juriaans AE, Kerkhof CE, Mahabier EE, et al. Temple syndrome: clinical findings, body composition and cognition in 15 patients. J Clin Med 11: 6289, 2020.","DOI":"10.3390\/jcm11216289"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lim K, Haider A, Sleigh A, Savage DB. Lipodystrophy: a paradigm for understanding the consequences of &quot;overloading&quot; adipose tissue. Physiol Rev 101: 907-993, 2021.","DOI":"10.1152\/physrev.00032.2020"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pinnick KE, Nicholson G, Manolopoulos KN, et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63: 3785-3797, 2014.","DOI":"10.2337\/db14-0385"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Klein S, Gastaldelli A, Yki-j\u00e4rvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab 34: 11-20, 2022.","DOI":"10.1016\/j.cmet.2021.12.012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010: 476279, 2010.","DOI":"10.1155\/2010\/476279"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chen VL, Wright AP, Halligan B, et al. Body composition and genetic lipodystrophy risk score associate with nonalcoholic fatty liver disease and liver fibrosis. Hepatol Commun 3: 1073-1084, 2019.","DOI":"10.1002\/hep4.1391"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sandino J, Martin-Taboada M, Medina-Gomez G, Vila-Bedmar R, Morales E. Novel insights in the physiopathology and management of obesity-related kidney disease. Nutrients 14: 3937, 2022.","DOI":"10.3390\/nu14193937"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gomes LG, Cunha-Silva M, Crespo RP, et al. <i>DLK1<\/i> is a novel link between reproduction and metabolism. J Clin Endocrinol Metab 104: 2112-2120, 2019.","DOI":"10.1210\/jc.2018-02010"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rhee M, Lee SH, Kim JW, et al. Preadipocyte factor 1 induces pancreatic ductal cell differentiation into insulin-producing cells. Sci Rep 6: 23960, 2016.","DOI":"10.1038\/srep23960"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996.","DOI":"10.1056\/NEJM199602013340503"},{"key":"28","unstructured":"28. Son C, Hosoda K, Nakao K. Leptin resistance. Nippon Rinsho (Jpn J Clin Med) 72: 302-306, 2014 (in Japanese)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Clerc A, Coupaye M, Mosbah H, et al. Diabetes mellitus in Pader-Willi syndrome: natural history during the transition from childhood to adulthood in a cohort of 39 patients. J Clin Med 10: 5310, 2021.","DOI":"10.3390\/jcm10225310"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Manzoni MF, Pramparo T, Stroppolo A, et al. A patient with maternal chromosome 14 UPD presenting with a mild phenotype and MODY. Clin Gen 57: 406-408, 2000.","DOI":"10.1034\/j.1399-0004.2000.570514.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Katahira M, Kayashima T, Kishino T, Niikawa N. Maternal uniparental disomy for cromosome 14 with diabetes mellitus. Inter Med 41: 717-721, 2002.","DOI":"10.2169\/internalmedicine.41.717"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kimura T, Kagami M, Matsubara K, Yatsuga S, Mukasa R. Temple syndrome diagnosed in an adult patient with clinical autism spectrum disorder. Clin Case Rep 7: 15-18, 2019.","DOI":"10.1002\/ccr3.1895"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Monk D, Morales J, den Dunnen JT, et al.; Nomenclature group of the European Network for Human Congenital Imprinting Disorders. Recommendations for a nomenclature system for reporting methylation aberrations in imprinted domains. Epigenetics 13: 117-121, 2018.","DOI":"10.1080\/15592294.2016.1264561"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/2\/64_2743-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T03:29:24Z","timestamp":1737170964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/2\/64_2743-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2743-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"2743-23"}}